Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：70
|
作者：
Boucau, Julie [1 ]
Uddin, Rockib [2 ]
Marino, Caitlin [1 ]
Regan, James [3 ]
Flynn, James P. [3 ]
Choudhary, Manish C. [3 ,4 ]
Chen, Geoffrey [2 ]
Stuckwisch, Ashley M. [2 ]
Mathews, Josh [2 ]
Liew, May Y. [2 ]
Singh, Arshdeep [2 ]
Reynolds, Zahra [2 ]
Iyer, Surabhi L. [2 ]
Chamberlin, Grace C. [2 ]
Vyas, Tammy D. [2 ]
Vyas, Jatin M. [2 ,4 ]
Turbett, Sarah E. [2 ]
Li, Jonathan Z. [3 ,4 ]
Lemieux, Jacob E. [2 ,4 ,5 ]
Barczak, Amy K. [1 ,2 ,4 ]
Siedner, Mark J. [2 ,4 ]
机构：
[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02215 USA
[5] Broad Inst, Cambridge, MA 02138 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期
关键词：
COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;
D O I：
10.1093/cid/ciac512
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
引用
收藏
页码：E526 / E529
页数：4
相关论文
共 50 条
  • [41] Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis
    Chen, I-Wen
    Yu, Ting-Sian
    Lin, Chien-Hung
    Hung, Kuo-Chuan
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (06)
  • [42] Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19
    Zhang, Huan
    Tan, Xiaojiao
    Chen, Junjun
    Zhang, Zheng
    Wang, Chenxi
    Shi, Haiqing
    Li, Yao
    Li, Jianbo
    Kang, Yan
    Jin, Xiaodong
    Liao, Xuelian
    [J]. BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)
  • [43] The Coronavirus Disease 2019 (COVID-19) Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls
    Pandit, Jay A.
    Radin, Jennifer M.
    Chiang, Danielle C.
    Spencer, Emily G.
    Pawelek, Jeff B.
    Diwan, Mira
    Roumani, Leila
    Mina, Michael J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 77 (01) : 25 - 31
  • [44] A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019
    Haslam, Alyson
    Prasad, Vinay
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [45] COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy
    Coulson, J. M.
    Adams, A.
    Gray, L. A.
    Evans, A.
    [J]. JOURNAL OF INFECTION, 2022, 85 (04) : 476 - 477
  • [46] Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals
    Smith-Jeffcoat, Sarah E.
    Biddle, Jessica E.
    Talbot, H. Keipp
    Morrissey, Kerry Grace
    Stockwell, Melissa S.
    Maldonado, Yvonne
    McLean, Huong Q.
    Ellingson, Katherine D.
    Bowman, Natalie M.
    Asturias, Edwin
    Mellis, Alexandra M.
    Johnson, Sheroi
    Kirking, Hannah L.
    Rolfes, Melissa A. R.
    Olivo, Vanessa
    Merrill, Lori
    Battan-Wraith, Steph
    Sano, Ellen
    McLaren, Son H.
    Vargas, Celibell Y.
    Goodman, Sara
    Sarnquist, Clea C.
    Govindaranjan, Prasanthi
    Petrie, Joshua G.
    Belongia, Edward A.
    Ledezma, Karla
    Pryor, Kathleen
    Lutrick, Karen
    Bullock, Ayla
    Yang, Amy
    Haehnel, Quenla
    Rao, Suchitra
    Zhu, Yuwei
    Schmitz, Jonathan
    Hart, Kimberly
    Grijalva, Carlos G.
    Salvatore, Phillip P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, : 1175 - 1184
  • [47] SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy ( vol 176 , pg 1577 , 2023)
    Edelstein, G. E.
    Boucau, J.
    Uddin, R.
    [J]. ANNALS OF INTERNAL MEDICINE, 2024, 177 (04)
  • [48] Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
    Lin, Chih-Wei
    Liang, Yu-Ling
    Chuang, Ming-Ta
    Tseng, Chun-Han
    Tsai, Pei-Yin
    Su, Mei-Tsz
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (12) : 1942 - 1946
  • [49] Effectiveness of molnupiravir and nirmatrelvir-ritonavir in patients hospitalized with COVID-19: A target trial emulation study
    Yan, Vincent Ka Chun
    Wan, Eric Yuk Fai
    Mok, Anna Hoi Ying
    Chan, Esther Wai Yin
    Wong, Ian Chi Kei
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 264 - 264
  • [50] Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19
    Zeng, Guangting
    Wang, Linlin
    Li, Jianqiang
    Zhang, Zanling
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (06)
12345